# A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

> **NCT04998331** · — · COMPLETED · sponsor: **Takeda** · enrollment: 51 (actual)

## Conditions studied

- Hodgkin Disease
- Lymphoma, T-Cell, Cutaneous

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT04998331
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2022-04-30
- **Final completion:** 2023-09-07
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04998331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04998331, "A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04998331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*